应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BMY 施贵宝
休市中 05-03 16:00:00 EDT
43.99
+0.29
+0.66%
盘后
43.99
+0.00
0.00%
19:59 EDT
最高
44.33
最低
43.69
成交量
1,210万
今开
43.90
昨收
43.70
日振幅
1.48%
总市值
891.72亿
流通市值
889.91亿
总股本
20.27亿
成交额
5.32亿
换手率
0.60%
流通股本
20.23亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
日本小野制药公司称 24 亿美元收购 Deciphera 是全球扩张的 "第一步
Reuters · 04-30
日本小野制药公司称 24 亿美元收购 Deciphera 是全球扩张的 "第一步
全球首创心肌肌球蛋白抑制剂迈凡妥®(玛伐凯泰胶囊)在中国获批
美通社 · 04-30
全球首创心肌肌球蛋白抑制剂迈凡妥®(玛伐凯泰胶囊)在中国获批
Repertoire与百时美施贵宝合作开发3款自免疫苗-36氪
智通财经 · 04-30
Repertoire与百时美施贵宝合作开发3款自免疫苗-36氪
Repertoire与百时美施贵宝(BMY.US)合作开发3款自免疫苗
智通财经网 · 04-29
Repertoire与百时美施贵宝(BMY.US)合作开发3款自免疫苗
施贵宝2024财年第一财季实现净利润-119.11亿美元,同比减少626.57%
自选股智能写手 · 04-27
施贵宝2024财年第一财季实现净利润-119.11亿美元,同比减少626.57%
百时美施贵宝上涨1.21%,报45.24美元/股
金融界 · 04-26
百时美施贵宝上涨1.21%,报45.24美元/股
更新 1-标普 500 第一季度盈利前景本周有所改善 -LSEG
Reuters · 04-26
更新 1-标普 500 第一季度盈利前景本周有所改善 -LSEG
百时美施贵宝公司公布截至三月份的季度业绩 - 收益摘要
Reuters · 04-26
百时美施贵宝公司公布截至三月份的季度业绩 - 收益摘要
施贵宝2023财年实现净利润80.25亿美元,同比增加26.84%
自选股智能写手 · 04-26
施贵宝2023财年实现净利润80.25亿美元,同比增加26.84%
施贵宝一季度销售额118.65亿美元,同比增4.66%,高于预期
智通财经网 · 04-25
施贵宝一季度销售额118.65亿美元,同比增4.66%,高于预期
BUZZ-布里斯托尔-迈尔斯公司陷入亏损,创四年多新低
Reuters · 04-25
BUZZ-布里斯托尔-迈尔斯公司陷入亏损,创四年多新低
施贵宝(BMY)跌逾7% 一季度盈转亏 大幅下调今年盈利预期
金吾财讯 · 04-25
施贵宝(BMY)跌逾7% 一季度盈转亏 大幅下调今年盈利预期
百时美施贵宝下跌5.1%,报46.37美元/股
金融界 · 04-25
百时美施贵宝下跌5.1%,报46.37美元/股
施贵宝盘中异动 早盘股价大跌5.08%报46.38美元
自选股智能写手 · 04-25
施贵宝盘中异动 早盘股价大跌5.08%报46.38美元
百时美施贵宝Q1由盈转亏 大幅下调今年盈利预期
金融界 · 04-25
百时美施贵宝Q1由盈转亏 大幅下调今年盈利预期
更新版 1-百时美施贵宝公布季度亏损,收入增长 5
Reuters · 04-25
更新版 1-百时美施贵宝公布季度亏损,收入增长 5
百时美施贵宝公司第一季度营收118.7亿美元,预估114.5亿美元
华尔街见闻 · 04-25
百时美施贵宝公司第一季度营收118.7亿美元,预估114.5亿美元
BUZZ-交易成本影响 2024 年前景,百时美施贵宝业绩下滑
Reuters · 04-25
BUZZ-交易成本影响 2024 年前景,百时美施贵宝业绩下滑
媒体-百时美施贵宝起草应对美国限制中国制药的应急计划 - FT
Reuters · 04-25
媒体-百时美施贵宝起草应对美国限制中国制药的应急计划 - FT
未来一天的看点 - 4月25日星期四
Reuters · 04-25
未来一天的看点 - 4月25日星期四
暂无数据
公司概况
公司名称:
施贵宝
所属市场:
NYSE
上市日期:
--
主营业务:
百时美施贵宝公司于1933年8月根据特拉华州法律注册成立,名为百时美公司,继承了1887年在纽约成立的一家企业。1989年,由于合并,公司更名为百时美施贵宝公司。公司在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。他们在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。 他们预计他们对Celgene和MyoKardia的收购将进一步将他们定位为领先的生物制药公司,通过多项近期资产和额外的外部合作伙伴扩大他们的肿瘤学、血液学、免疫学和心血管产品组合。
发行价格:
--
{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":43.99,"timestamp":1714766400000,"preClose":43.7,"halted":0,"volume":12104488,"hourTrading":{"tag":"盘后","latestPrice":43.99,"preClose":43.99,"latestTime":"19:59 EDT","volume":335294,"amount":14749442.6582,"timestamp":1714780770547},"delay":0,"floatShares":2022972717,"shares":2027100096,"eps":-3.002585,"marketStatus":"休市中","marketStatusCode":7,"change":0.29,"latestTime":"05-03 16:00:00 EDT","open":43.9,"high":44.33,"low":43.685,"amount":532079339.39116,"amplitude":0.01476,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.002585,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714982400000},"adr":0,"listingDate":-18475200000,"adjPreClose":43.7,"adrRate":0,"dividendRate":0.053194,"preHourTrading":{"tag":"盘前","latestPrice":43.92,"preClose":43.7,"latestTime":"09:29 EDT","volume":17041,"amount":747729.121922,"timestamp":1714742998537},"postHourTrading":{"tag":"盘后","latestPrice":43.99,"preClose":43.99,"latestTime":"19:59 EDT","volume":335294,"amount":14749442.6582,"timestamp":1714780770547},"volumeRatio":0.7150838382827106},"requestUrl":"/m/hq/s/BMY/tweets","defaultTab":"tweets","newsList":[{"id":"2431369005","title":"日本小野制药公司称 24 亿美元收购 Deciphera 是全球扩张的 \"第一步","url":"https://stock-news.laohu8.com/highlight/detail?id=2431369005","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2431369005?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:41","pubTimestamp":1714462881,"startTime":"0","endTime":"0","summary":" Rocky Swift 路透东京4月30日 - 日本小野制药公司 周二表示,它以24亿美元收购Deciphera Pharmaceuticals 是拓展美国和欧洲市场的 \"第一步\"。该药预计将从 2028 年起在主要市场失去专利保护。此次收购包括Deciphera公司用于治疗一种胃肠道癌症的口服药物Qinlock,该药于2020年获得美国食品和药物管理局的全面批准。数字Ono Pharma 的现金收购价为每股 25.60 美元,比总部位于美国的 Deciphera 之前的收盘价溢价 74.7%。Deciphera股价则大涨73%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431510603","title":"全球首创心肌肌球蛋白抑制剂迈凡妥®(玛伐凯泰胶囊)在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2431510603","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2431510603?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:04","pubTimestamp":1714457040,"startTime":"0","endTime":"0","summary":"作为全球首创的心肌肌球蛋白抑制剂,迈凡妥可靶向疾病核心病理生理机制,通过与心肌肌球蛋白的可逆性结合,减少肌球蛋白和肌动蛋白横桥的数量,以减轻心肌的过度收缩,并改善舒张功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4401067_ZH01067_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431062308","title":"Repertoire与百时美施贵宝合作开发3款自免疫苗-36氪","url":"https://stock-news.laohu8.com/highlight/detail?id=2431062308","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431062308?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:00","pubTimestamp":1714438815,"startTime":"0","endTime":"0","summary":"4月29日,率先发现和开发可编程T细胞靶向免疫药物的生物技术公司Repertoire Immune Medicines宣布与百时美施贵宝达成合作协议,开发针对3种自免疾病的“耐受疫苗”,该合作旨在通过重置免疫系统,为患有自身免疫疾病的患者开发有效、选择性和持久的治疗方法。根据协议条款,Repertoire将获得6500万美元的预付款,以及高达18亿美元的预付款,用于实现开发、监管和商业里程碑,此外还将获得分级特许权使用费。(智通财经)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043009001887c17471&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043009001887c17471&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431570758","title":"Repertoire与百时美施贵宝(BMY.US)合作开发3款自免疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2431570758","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2431570758?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:07","pubTimestamp":1714396064,"startTime":"0","endTime":"0","summary":"Repertoire与施贵宝(BMY.US)合作开发3款自免疫苗。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20240429/20240429210359_68247.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240429/20240429210359_68247.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1115059.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430730380","title":"施贵宝2024财年第一财季实现净利润-119.11亿美元,同比减少626.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430730380","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430730380?lang=zh_cn&edition=full","pubTime":"2024-04-27 06:25","pubTimestamp":1714170303,"startTime":"0","endTime":"0","summary":"3月31日,施贵宝公布财报,公告显示公司2024财年第一财季净利润为-119.11亿美元,同比减少626.57%;其中营业收入为118.65亿美元,同比增加4.66%,每股基本收益为-5.89美元。机构评级:截至2024年3月31日,当前有22家机构对施贵宝目标价做出预测,其中目标均价为53.61美元,其中最低目标价为37.00美元,最高目标价为75.00美元。百时美施贵宝的一个重点是免疫肿瘤学,该公司是药物开发的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404270625148b58a652&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404270625148b58a652&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430201385","title":"百时美施贵宝上涨1.21%,报45.24美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430201385","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430201385?lang=zh_cn&edition=full","pubTime":"2024-04-26 23:02","pubTimestamp":1714143743,"startTime":"0","endTime":"0","summary":"4月26日,百时美施贵宝(BMY)盘中上涨1.21%,截至23:02,报45.24美元/股,成交2.04亿美元。财务数据显示,截至2024年03月31日,百时美施贵宝收入总额118.65亿美元,同比增长4.66%;归母净利润-119.11亿美元,同比减少626.57%。大事提醒:4月25日,百时美施贵宝2024财年一季报归属股东应占溢利-119.1亿美元,同比下降626.57%,基本每股收益-5.89美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/26230240441298.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430325638","title":"更新 1-标普 500 第一季度盈利前景本周有所改善 -LSEG","url":"https://stock-news.laohu8.com/highlight/detail?id=2430325638","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430325638?lang=zh_cn&edition=full","pubTime":"2024-04-26 03:45","pubTimestamp":1714074330,"startTime":"0","endTime":"0","summary":"LSEG周四的数据显示 , 标普500指数2024年第一季度的同比盈利增长率目前 为4.3%。这一数字高于 前一天的 3.3%。最新的估计是基于标准普尔500 指数中190家公司的业绩和对其他公司的预测,其中约78%的报告超过了分析师的盈利预期。根据LSEG的估计,如果没有这项一次性支出,标准普尔500指数的收益预计将同比增长7.4%。然而,尽管季度盈利前景有所改善,但周四股市仍出现下跌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430243230","title":"百时美施贵宝公司公布截至三月份的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2430243230","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430243230?lang=zh_cn&edition=full","pubTime":"2024-04-26 02:19","pubTimestamp":1714069169,"startTime":"0","endTime":"0","summary":" * 百时美施贵宝公司公布,在截至 3 月份的季度调整后每股亏损 4.40 美元,低于去年同期的每股收益 2.05 美元。18位分析师对该季度的平均预期是每股亏损4.44美元。华尔街预期为每股亏损 4.78 美元至 3.27 美元。* 百时美施贵宝公司公布的本季度每股收益为亏损5.89美元。* 该公司当季亏损 119.1 亿美元。* 本季度百时美施贵宝公司股价下跌了 9.9%,今年迄今为止下跌了 4.8%。华尔街对百时美施贵宝公司 12 个月目标价的中位数为 55.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430232344","title":"施贵宝2023财年实现净利润80.25亿美元,同比增加26.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430232344","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430232344?lang=zh_cn&edition=full","pubTime":"2024-04-26 01:23","pubTimestamp":1714065803,"startTime":"0","endTime":"0","summary":"12月31日,施贵宝公布财报,公告显示公司2023财年净利润为80.25亿美元,同比增加26.84%;其中营业收入为450.06亿美元,同比减少2.50%,每股基本收益为3.88美元。机构评级:截至2023年12月31日,当前有23家机构对施贵宝目标价做出预测,其中目标均价为55.70美元,其中最低目标价为40.00美元,最高目标价为75.00美元。百时美施贵宝近70%的总销售额来自美国,显示出对美国市场的依赖程度高于大多数同行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042601233087b01c9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042601233087b01c9c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"1128992656","title":"施贵宝一季度销售额118.65亿美元,同比增4.66%,高于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1128992656","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/1128992656?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:31","pubTimestamp":1714055519,"startTime":"0","endTime":"0","summary":"每股亏损为4.40美元,上年同期每股收益2.05美元,同比下降了314.63%。","market":"us","thumbnail":"https://static.tigerbbs.com/6d47bcbbea437d87e2dd64ff70026292","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6d47bcbbea437d87e2dd64ff70026292"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1110516.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2430284223","title":"BUZZ-布里斯托尔-迈尔斯公司陷入亏损,创四年多新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2430284223","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430284223?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:27","pubTimestamp":1714055271,"startTime":"0","endTime":"0","summary":" (更新) 4月25日 - ** 制药商百时美施贵宝 股价下跌7.50%,创逾四年新低45.20美元。** 该公司第一季度每股亏损4.40美元,受近期收购费用的影响--根据LSEG数据,分析师预期为每股亏损4.41美元。** BMY 去年同期调整后每股收益为 2.05 美元。** BMY第一季度营收为118.7亿美元,高于分析师预期的114.8亿美元。** 还宣布了到 2025 年底节省约 15 亿美元成本的计划** 今年以来股价下跌约 12","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430281778","title":"施贵宝(BMY)跌逾7% 一季度盈转亏 大幅下调今年盈利预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2430281778","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2430281778?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:05","pubTimestamp":1714053912,"startTime":"0","endTime":"0","summary":"金吾财讯 | 施贵宝(BMY)跌7.03%,报45.44美元,成交额3.11亿美元。施贵宝公布2024年第一季度业绩,销售额为118.65亿美元,同比增长4.66%,市场预期为114.58亿美元;每股亏损为4.40美元,较上年同期的每股盈利2.05美元由盈转亏,市场预期为每股亏损4.44美元。因收购事项影响,施贵宝下调今年盈利预期,该公司预计全年调整后的每股收益在0.40美元至0.70美元之间,远低于之前预期的7.10美元至7.40美元,与分析师预期的平均0.67美元相符。施贵宝计划在明年裁减2200个工作岗位,以实现到2025年底减少15亿美元成本的目标。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/Y2U1MTljZjZkNTgxMTYyODU5MDU0MTEzOA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2U1MTljZjZkNTgxMTYyODU5MDU0MTEzOA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"275264","is_publish_highlight":false,"gpt_icon":0},{"id":"2430289368","title":"百时美施贵宝下跌5.1%,报46.37美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430289368","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430289368?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:45","pubTimestamp":1714052726,"startTime":"0","endTime":"0","summary":"4月25日,百时美施贵宝(BMY)盘中下跌5.1%,截至21:45,报46.37美元/股,成交1.34亿美元。财务数据显示,截至2023年12月31日,百时美施贵宝收入总额450.06亿美元,同比减少2.5%;归母净利润80.25亿美元,同比增长26.84%。大事提醒:4月25日,百时美施贵宝(美东)盘前披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25214540414328.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430872286","title":"施贵宝盘中异动 早盘股价大跌5.08%报46.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430872286","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430872286?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:42","pubTimestamp":1714052521,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日21时42分,施贵宝股票出现异动,股价大幅下挫5.08%。施贵宝股票所在的制药行业中,整体跌幅为0.23%。因收购事项影响,百时美施贵宝下调今年盈利预期,该公司预计全年调整后的每股收益在0.40美元至0.70美元之间,远低于之前预期的7.10美元至7.40美元,与分析师预期的平均0.67美元相符。百时美施贵宝计划在明年裁减2200个工作岗位,以实现到2025年底减少15亿美元成本的目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240425214202861e90ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240425214202861e90ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430286833","title":"百时美施贵宝Q1由盈转亏 大幅下调今年盈利预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2430286833","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430286833?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:17","pubTimestamp":1714051074,"startTime":"0","endTime":"0","summary":"百时美施贵宝公布2024年第一季度业绩,销售额为118.65亿美元,同比增长4.66%,市场预期为114.58亿美元;每股亏损为4.40美元,较上年同期的每股盈利2.05美元由盈转亏,市场预期为每股亏损4.44美元。因收购事项影响,百时美施贵宝下调今年盈利预期,该公司预计全年调整后的每股收益在0.40美元至0.70美元之间,远低于之前预期的7.10美元至7.40美元,与分析师预期的平均0.67美元相符。百时美施贵宝计划在明年裁减2200个工作岗位,以实现到2025年底减少15亿美元成本的目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252135498b5332d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252135498b5332d8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430117409","title":"更新版 1-百时美施贵宝公布季度亏损,收入增长 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2430117409","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430117409?lang=zh_cn&edition=full","pubTime":"2024-04-25 19:45","pubTimestamp":1714045509,"startTime":"0","endTime":"0","summary":" Deena Beasley 路透社4月25日 - Bristol Myers Squibb 周四公布了第一季度亏损报告,原因是最近收购Karuna Therapeutics、RayzeBio和Mirati Therapeutics所产生的费用抵消了5%的收入增长。按净额计算,布里斯托尔公司的每股亏损为 5.89 美元。该公司此前预计每股收益为 7.10 美元至 7.40 美元。布里斯托尔公司表示,它仍然预计 2024 年的收入增长率为较低的个位数。他说,百时美施贵宝 \"有信心在今年实现加速增长\"。百时美施贵宝已经面临仿制药竞争的压力,Revlimid 曾是该公司最畅销的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430019704","title":"百时美施贵宝公司第一季度营收118.7亿美元,预估114.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430019704","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2430019704?lang=zh_cn&edition=full","pubTime":"2024-04-25 19:37","pubTimestamp":1714045037,"startTime":"0","endTime":"0","summary":"百时美施贵宝 公司第一季度营收118.7亿美元,预估114.5亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042519472987af1808&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042519472987af1808&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430406974","title":"BUZZ-交易成本影响 2024 年前景,百时美施贵宝业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2430406974","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430406974?lang=zh_cn&edition=full","pubTime":"2024-04-25 19:27","pubTimestamp":1714044435,"startTime":"0","endTime":"0","summary":" 4月25日 - ** 制药商百时美施贵宝 股价盘前下跌1.5%至48.14美元 ** 由于交易费用,百时美施贵宝将其 年度利润预期下调至每股 40 美分至 70 美分,而之前的预期为每股 7.10 美元至 7.40 美元。** BMY 去年同期调整后每股收益为 2.05 美元。** BMY第一季度营收为118.7亿美元,高于分析师预期的114.8亿美元。** 抗癌药物 Opdivo 的销售额为 20.8 亿美元,比预期低 2400 万美元。** 截至上一交易日收盘,BMY 累计下跌约 5","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430403982","title":"媒体-百时美施贵宝起草应对美国限制中国制药的应急计划 - FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2430403982","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430403982?lang=zh_cn&edition=full","pubTime":"2024-04-25 19:05","pubTimestamp":1714043116,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 4月25日 - -- 来源链接: -- 注:路透社未核实此报道,不保证其准确性","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430462500","title":"未来一天的看点 - 4月25日星期四","url":"https://stock-news.laohu8.com/highlight/detail?id=2430462500","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430462500?lang=zh_cn&edition=full","pubTime":"2024-04-25 02:30","pubTimestamp":1713983434,"startTime":"0","endTime":"0","summary":"美国劳工部的每周失业救济申请数据可能会显示,在截至4月20日的一周内,各州首次申请失业救济的人数增加了3000人,经季节性因素调整后为215000人。与此同时,首次领取失业救济金的人数可能从截至4月13日当周的181.2万人降至180.5万人。美国航空公司将公布第一季度财报。由于主要市场需求低迷,陶氏预计将公布第一季度收入下降的报告。烟草巨头 Altria 将公布第一季度业绩。受客户转向广告流媒体的帮助,Roku 第一季度收入预计将增长 14.52%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":-0.0192},{"period":"1month","weight":-0.157},{"period":"3month","weight":-0.0969},{"period":"6month","weight":-0.1672},{"period":"1year","weight":-0.3417},{"period":"ytd","weight":-0.1427}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月根据特拉华州法律注册成立,名为百时美公司,继承了1887年在纽约成立的一家企业。1989年,由于合并,公司更名为百时美施贵宝公司。公司在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。他们在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。 他们预计他们对Celgene和MyoKardia的收购将进一步将他们定位为领先的生物制药公司,通过多项近期资产和额外的外部合作伙伴扩大他们的肿瘤学、血液学、免疫学和心血管产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.013265},{"month":2,"riseRate":0.545455,"avgChangeRate":0.009113},{"month":3,"riseRate":0.636364,"avgChangeRate":0.008429},{"month":4,"riseRate":0.488889,"avgChangeRate":-0.002113},{"month":5,"riseRate":0.6,"avgChangeRate":0.005022},{"month":6,"riseRate":0.613636,"avgChangeRate":0.010539},{"month":7,"riseRate":0.409091,"avgChangeRate":-0.003649},{"month":8,"riseRate":0.5,"avgChangeRate":-0.004242},{"month":9,"riseRate":0.522727,"avgChangeRate":0.010569},{"month":10,"riseRate":0.568182,"avgChangeRate":0.024004},{"month":11,"riseRate":0.613636,"avgChangeRate":0.020382},{"month":12,"riseRate":0.636364,"avgChangeRate":0.022108}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}